22nd Century Group, Inc.
8201 Main Street
128 articles with 22nd Century Group, Inc.
Key Highlights: Net sales revenue increased approximately 11% to $6.4 million Gross profit continues to show improvement year-over-year as a result of targeted actions to improve margins and cost structure Operating loss improved by approximately $276 thousand Adjusted EBITDA improved 21% Appointed new CEO, James A. Mish and new CFO, John Franzino WILLIAMSVILLE, N.Y., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NYSE American: XXII) (“22nd Century” or “the Company”), a
6/5/2020Biopharma and life sciences companies bolster their leadership teams and board with these Movers & Shakers.
22nd Century Group Appoints James A. Mish as Chief Executive Officer and John Franzino as Chief Financial Officer
Mish brings extensive global executive leadership experience in the development, manufacturing and commercialization of active pharmaceutical ingredients, including cannabinoids, and related consumer products
22nd Century Group, Inc., a leading plant biotechnology company focused on reduced nicotine tobacco and hemp/cannabis plant genetics research and development, reported results for the first quarter ended March 31, 2020.
22nd Century Group Completes Successful Non-GMO Very Low Nicotine Content Tobacco Research Field Trials
Research Validates New Non-GMO Methodologies for Reducing Nicotine in Tobacco Plants by up to 99%
Maintains Strong Balance Sheet; Momentum Continues for Modified Risk Tobacco Product and Major Milestone Achieved in Hemp/Cannabis Research
22nd Century Group Adds to Leadership TeamNew Vice President of Acquisitions and New Director of Communications & Investor Relations Set to Drive Acquisition Efforts and Improve Investor Engagement
22nd Century Group, Inc. announced the appointment of Lisa Parks as its Vice President of Acquisitions and Mei Kuo as its new Director of Communications and Investor Relations.
22nd Century Builds Strong Momentum for its Very Low Nicotine Content Tobacco and Makes Significant Progress in the Development of Valuable New Hemp/Cannabis Plants
22nd Century Group, Inc., a plant biotechnology company that is focused on tobacco harm reduction, Very Low Nicotine Content tobacco and hemp/cannabis research, announced that the Company filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019 with the U.S. Securities and Exchange Commission.
Mr. Fleet has also been elected to serve as a member of the Company’s Board of Directors.
22nd Century Group, Inc. announced that the Company will provide a business update for investors on a conference call to be held Thursday, August 8, 2019, at 4:00 PM.
22nd Century Group, Inc. announced that President and Chief Executive Officer Henry Sicignano III has resigned for personal reasons, effective July 26, 2019.
22nd Century Files 2019 First Quarter Report and Announces Conference Call to Provide Business Update
22nd Century’s proposed VLN™ cigarettes continue to fall squarely within the nicotine range that public health officials anticipate will be mandated by the FDA.
Mr. Pritchard was formerly the Head of Regulatory Science for Imperial Brands, U.K.
22nd Century Announces Exclusive Worldwide Agreement with KeyGene for Genetic Development of Hemp/Cannabis
Strategic collaboration will bolster 22nd Century’s position as a global leader in hemp/cannabis genetics.
22nd Century has had more than 20 conversations with the FDA on matters relating to the Company’s PMT and MRTP applications
22nd Century’s New Study Confirms Very Low Nicotine Content Cigarettes Result in 97% Less Nicotine in Smoker’s Bloodstream
The results indicate that subjects using the VLNC product had 97% less nicotine in their blood as compared to their blood-nicotine levels after use of their usual brand of highly addictive commercial cigarettes.
The FDA has accepted for review the Company’s MRTPA for VLNTM cigarettes
Kaplan Fox & Kilsheimer LLP is investigating claims on behalf of investors of 22nd Century Group, Inc.
President Trump Signs Bill Legalizing Low-THC Cannabis